CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma
October 3rd 2022
Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.